Redmile Group invests in Hookipa's €33.2m series-D

The firm was joined by new investors Invus and Samsara BioCapital, as well as several current investors including Forbion.

The fresh capital will be primarily used to progress the clinical development of Hookipa's lead development programmes for the treatment of human papillomavirus-positive cancers. The company also plans to develop new immuno-oncology product candidates.

Previous funding
In 2011, Sofinnova Partners and Forbion invested €7m in a series-A round.

Sofinnova and Forbion then jointly led a €20m series-B round with participation from Takeda Ventures, Boehringer Ingelheim Venture Fund (BIVF) and BioMedPartners in 2013.

In 2017, a consortium of VC firms and specialist life sciences investors took part in a $59.6m series-C funding round led by an anonymous US public investment fund. It included new investors HB Partners, Hillhouse Capital, Sirona Capital and Gilead, and all previous investors in the company – including Sofinnova, Forbion, BIVF, Takeda and BioMedPartners.

Company
Based in Vienna and founded in 2011, Hookipa is a clinical-stage biopharmaceutical company developing immunotherapeutics. The company's proprietary arenavirus-based technologies include VaxWave, a replication-deficient viral vector; and TheraT, a replication-attenuated viral vector – both of which are in trial stages.

People
Hookipa – Joern Aldag (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Austria
• Venture
• Sofinnova Partners